NCT01382706 2025-10-09
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Phase 2 Terminated
Clinical Trials
13 trialsNCT00953576 2018-09-04
KHLAD
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00158782 2017-11-17
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00246753 2017-06-28
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00949455 2015-04-15
LaMB
Queen Mary University of London
Phase 2/3 Unknown
NCT00103194 2014-09-30
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00313599 2014-07-02
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT00623064 2014-07-01
Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT00095667 2013-05-08
Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01700010 2013-01-17
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT01245660 2013-01-11
LAPAINBLAD
University Hospital, Bordeaux
Phase EARLY_PHASE1 Terminated
NCT00447226 2012-06-12
Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
GlaxoSmithKline
Phase 2 Terminated